Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Lifestyle drugs - Determining their value and who should pay
Autore:
Mitrany, D;
Indirizzi:
Adv PCS, Scottsdale, AZ 85260 USA Adv PCS Scottsdale AZ USA 85260Adv PCS, Scottsdale, AZ 85260 USA
Titolo Testata:
PHARMACOECONOMICS
fascicolo: 5, volume: 19, anno: 2001,
parte:, 1
pagine: 441 - 448
SICI:
1170-7690(2001)19:5<441:LD-DTV>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
ERECTILE DYSFUNCTION; PLAN; COST;
Tipo documento:
Editorial Material
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
34
Recensione:
Indirizzi per estratti:
Indirizzo: Mitrany, D Adv PCS, 9501 E Shea Blvd,MC 034, Scottsdale, AZ 85260 USA Adv PCS 9501 E Shea Blvd,MC 034 Scottsdale AZ USA 85260 260 USA
Citazione:
D. Mitrany, "Lifestyle drugs - Determining their value and who should pay", PHARMACOECO, 19(5), 2001, pp. 441-448

Abstract

Lifestyle drugs are used to alleviate or enhance: (i) lifestyle problems or conditions, regardless of the cause; and (ii) health problems for which the underlying cause is in the realm of personal responsibility. It is the particular use of a drug, rather than its inherent properties, that determines whether it is called a lifestyle drug. The increasing availability of, and high demand for, lifestyle drugs contributes to their expanding role in healthcare. In the absence of objective pharmacoeconomic data, the subjective value orcost effectiveness of these agents varies among patients, medical professionals, regulatory agencies and payers. Most nations rely on value systems that are implied, rather than clearly articulated. The aims of largely institutional payers, and the individual patients and their physicians do not always coincide, creating tensions over who should pay for these drugs. Cost-sharing between patient and payer, drug limitations and prior authorisation protocols are some methods used to manage accessto these drugs. There is an urgent need to formulate coherent values, priorities and strategies for dealing with lifestyle drugs. To do this, local and national regulatory agencies, politicians, healthcare providers, insurers and patients need to formulate broad areas of consensus. Finally, we must not forget compassion for the patient as: we apply the dictates of institutional policy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/04/20 alle ore 20:05:03